Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Shannon

Showing results (61-70 of 111) with videos related to

Pageof 12
Sort By:
Nature Communications|February 9, 2016
KRAS insertion mutations are oncogenic and exhibit distinct functional propertiesYasmine White, Aditi Bagchi, Jessica Van Ziffle, et al.
Bioorganic & Medicinal Chemistry Letters|October 19, 2021
Chemical proteomic analysis of palmostatin beta-lactone analogs that affect N-Ras palmitoylationRadu M Suciu, Irungu K Luvaga, Akram Hazeen, et al.
Cell Reports|April 11, 2019
High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality PredictionsMarsilius Mues, Laila Karra, Damia Romero-Moya, et al.
Blood|December 29, 2006
K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cellsMargaret E M Van Meter, Ernesto Díaz-Flores, Joehleen A Archard, et al.
Blood|July 3, 2013
Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylationJing Lu, Tatiana Zavorotinskaya, Yumin Dai, et al.
Journal of the American Medical Informatics Association : JAMIA|March 3, 2007
Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicitiesEthan Basch, David Artz, Alexia Iasonos, et al.
Plos One|May 26, 2018
Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapyOlga Ksionda, Marsilius Mues, Anica M Wandler, et al.
Molecular Cancer Therapeutics|August 28, 2020
<i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEKDaniela Pucciarelli, Steven P Angus, Benjamin Huang, et al.
The Western Journal of Emergency Medicine|April 29, 2026
Reducing Emergency Diagnostic Uncertainty with TRACE: Triage and Risk Assessment via Cost EstimationKian D Samadian, Paul Chong, Boyu Peng, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 3, 2010
Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agentsMonique Dail, Qing Li, Andrew McDaniel, et al.
Pageof 12

Showing results (61-70 of 111) with videos related to

Sort By:
Pageof 12
Nature Communications|February 9, 2016
KRAS insertion mutations are oncogenic and exhibit distinct functional propertiesYasmine White, Aditi Bagchi, Jessica Van Ziffle, et al.
Bioorganic & Medicinal Chemistry Letters|October 19, 2021
Chemical proteomic analysis of palmostatin beta-lactone analogs that affect N-Ras palmitoylationRadu M Suciu, Irungu K Luvaga, Akram Hazeen, et al.
Cell Reports|April 11, 2019
High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality PredictionsMarsilius Mues, Laila Karra, Damia Romero-Moya, et al.
Blood|December 29, 2006
K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cellsMargaret E M Van Meter, Ernesto Díaz-Flores, Joehleen A Archard, et al.
Blood|July 3, 2013
Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylationJing Lu, Tatiana Zavorotinskaya, Yumin Dai, et al.
Journal of the American Medical Informatics Association : JAMIA|March 3, 2007
Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicitiesEthan Basch, David Artz, Alexia Iasonos, et al.
Plos One|May 26, 2018
Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapyOlga Ksionda, Marsilius Mues, Anica M Wandler, et al.
Molecular Cancer Therapeutics|August 28, 2020
<i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEKDaniela Pucciarelli, Steven P Angus, Benjamin Huang, et al.
The Western Journal of Emergency Medicine|April 29, 2026
Reducing Emergency Diagnostic Uncertainty with TRACE: Triage and Risk Assessment via Cost EstimationKian D Samadian, Paul Chong, Boyu Peng, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 3, 2010
Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agentsMonique Dail, Qing Li, Andrew McDaniel, et al.
Pageof 12